Salinomycin, as an autophagy modulator-- a new avenue to anticancer: a review

Area of Science:

• Oncology
• Cell Biology

Background:

• Salinomycin (Sal) has demonstrated efficacy against breast cancer stem cells since 2009.
• Sal exhibits anticancer properties, including proliferation inhibition, cell death induction, and metastasis suppression in various human cancers, both in vitro and in vivo.
• Unlike conventional chemotherapy, Sal presents a favorable side effect profile.

Purpose of the Study:

• To systematically review the involvement of autophagy in Salinomycin's anticancer effects.
• To elucidate the mechanisms by which autophagy contributes to Sal's efficacy against cancer cells.
• To highlight the distinctive role of autophagy in Sal's cancer-targeting capabilities.

Main Methods:

• Literature review of preclinical and clinical studies on Salinomycin and cancer.
• Analysis of research investigating the interplay between Salinomycin and autophagic pathways.
• Synthesis of evidence regarding the dual role of autophagy in Salinomycin's mechanism of action.

Main Results:

• Autophagy plays a critical and potentially novel role in Salinomycin's anticancer activities.
• Salinomycin appears to modulate autophagy in a manner that preferentially targets cancer cells.
• Evidence suggests a dual role for Salinomycin in autophagy, contributing to its selective cytotoxicity.

Conclusions:

• Autophagy is a key mediator of Salinomycin's potent anticancer effects.
• The selective targeting of cancer cells by Salinomycin may be attributed to its complex interaction with autophagy.
• Further research is warranted to validate these findings and develop Salinomycin as a targeted cancer therapeutic.